Internal medicine

Mann–Whitney U test

Pathology

Disease

Coronavirus disease 2019 (COVID-19)

Infectious disease (medical specialty)

Outbreak

Psychiatry

Surgery

Cognition

Physical therapy

Wilcoxon signed-rank test

Montreal Cognitive Assessment

2019-20 coronavirus outbreak

Cognitive impairment

Hyperbaric oxygen

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Medicine

Clinical Medicine

<h3>Background</h3> Long COVID is a common occurrence following COVID-19 infection. The most common symptom reported is fatigue. Limited interventional treatment options exist. We report the first evaluation of hyperbaric oxygen therapy (HBOT) for long COVID treatment. <h3>Methods</h3> A total of 10 consecutive patients received 10 sessions of HBOT to 2.4 atmospheres over 12 days. Each treatment session lasted 105 minutes, consisting of three 30-minute exposures to 100% oxygen, interspersed with 5-minute air breaks. Validated fatigue and cognitive scoring assessments were performed at day 1 and 10. Statistical analysis was with Wilcoxon signed-rank testing reported alongside effect sizes. <h3>Results</h3> HBOT yielded a statistically significant improvement in the Chalder fatigue scale (p=0.0059; d=1.75 (very large)), global cognition (p=0.0137; d=–1.07 (large)), executive function (p=0.0039; d=–1.06 (large)), attention (p=0.0020; d=–1.2 (very large)), information processing (p=0.0059; d=–1.25 (very large)) and verbal function (p=0.0098; d=–0.92 (large)). <h3>Conclusion</h3> Long COVID-related fatigue can be debilitating, and may affect young people who were previously in economic employment. The results presented here suggest potential benefits of HBOT, with statistically significant results following 10 sessions.

Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention